News for OPKO Health, Inc. (OPK)

OPKO Health, Inc. (NASDAQ:OPK) is one of the Best American Penny Stocks to Buy According to Analysts. On July 8, OPKO Health, Inc. (NASDAQ:OPK) in collaboration with Entera Bio Ltd. (NASDAQ: ENTX) announced the selection of their Oral GLP-2 Analog for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism Congress. This […]

Opko Health Inc. (NASDAQ:OPK) is one of the 13 Stocks Under $5 With High Upside Potential. On May 1, analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK), retaining the price target of $3.00. Despite mixed fiscal Q1 2025 results, the rating was supported by future prospects and strategic […]

OPKO Health, Inc. (NASDAQ:OPK) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the company, in partnership with Entera Bio Ltd., announced that new data for their investigational oral OPK-88006 tablet treatment has been selected for presentation at ENDO 2025. ENDO 2025 is the 2025 chapter of […]

On June 18, Société Générale's Subadra Rajappa appeared on CNBC to talk about her expectations from the Fed.

OPKO Health has improved its financial position by selling most of BioReference, reducing cash burn, and strengthening its balance sheet.

Summary OPKO Health Inc (OPK) has announced the establishment of a Scientific Advisory Board for its subsidiary, ModeX Therapeutics, as of June 9, 2025. The boa

Will provide expertise across ModeX's portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer

MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ( OPK) announced today that management will be participating in two investor conferences over the co

Investment Highlights: OPKO Health is currently in oversold territory, potentially indicating a rebound opportunity. Analysts provide a wide price target

On May 1, 2025, Barrington Research analyst Michael Petusky reaffirmed his positive outlook on OPKO Health (OPK), maintaining an "Outperform" rating. The analys

Diagnostics Segment Revenue: $102.8 million in Q1 2025, including $25.1 million from assets being sold to LabCorp, compared to $126.9 million in Q1 2024.Diagno

Apr 30, 2025 / 08:30PM GMTOperator Good afternoon, and welcome to the OPKO Health first-quarter 2025 financial results conference call. (Operator Instructions)

OPKO Health's strategic sale to Labcorp aims to bolster profitability and streamline operations. The company's revenue guidance projects a strong outloo

OPKO Health Q1 2025 earnings call highlights strategic moves, including the Labcorp sale and pharmaceutical advancements.

OPKO Health, Inc. (NASDAQ:OPK) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.

The headline numbers for OPKO Health (OPK) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Conference call begins at 4:30 p.m. Eastern time today MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ( OPK) reports business highlights and fi

Revenue: Reported $149.9 million for Q1 2025, falling short of the estimated $164.26 million.Earnings Per Share (EPS): Recorded a net loss of $0.10 per share,

Teva and Nova led the gains today but Hapoalim and Leumi fell sharply.